Chemocentryx Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 178

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.7B

Chemocentryx General Information

Description

Developer of administered small molecule therapeutics based in Mountain View, California. The company offers orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 850 Maude Avenue
  • Mountain View, CA 94043
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 850 Maude Avenue
  • Mountain View, CA 94043
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chemocentryx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 20-Oct-2022 $3.7B Completed Generating Revenue
12. Secondary Transaction - Open Market Completed Generating Revenue
11. PIPE 04-Jan-2018 Completed Generating Revenue
10. PIPE 11-May-2016 Completed Clinical Trials - Phase 3
9. Secondary Transaction - Open Market 31-Mar-2014 Completed Generating Revenue
8. Secondary Transaction - Open Market 28-Mar-2013 Completed Generating Revenue
7. IPO 08-Feb-2012 Completed Pre-Clinical Trials
6. IPO 14-Nov-2008 Cancelled Generating Revenue
5. Later Stage VC (Series E) 05-Sep-2008 $50M $164M Completed Generating Revenue
4. Later Stage VC (Series D) 22-Mar-2007 $29.8M $114M Completed Generating Revenue
To view Chemocentryx’s complete valuation and funding history, request access »

Chemocentryx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B
Series A3
Series A2 1,000,000 $0.001000 $1 $1 1x $1 1.47%
Series A1 3,000,000 $0.001000 $1 $1 1x $1 4.41%
To view Chemocentryx’s complete cap table history, request access »

Chemocentryx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of administered small molecule therapeutics based in Mountain View, California. The company offers orally-admi
Drug Discovery
Mountain View, CA
178 As of 2021

Mainz, Germany
 

Richmond, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Chemocentryx Competitors (21)

One of Chemocentryx’s 21 competitors is BioNTech, a Formerly VC-backed company based in Mainz, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioNTech Formerly VC-backed Mainz, Germany
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Arno Therapeutics Formerly VC-backed Flemington, NJ
Bristol-Myers Squibb Corporation Princeton, NJ
You’re viewing 5 of 21 competitors. Get the full list »

Chemocentryx Patents

Chemocentryx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023255619-A1 Ccr4 antagonists Pending 19-Apr-2022
EP-4511368-A2 Ccr4 antagonists Pending 19-Apr-2022
EP-4511368-A4 Ccr4 antagonists Pending 19-Apr-2022
JP-2023159050-A Ccr4 antagonists Pending 19-Apr-2022
US-20230382894-A1 Ccr4 antagonists Pending 19-Apr-2022 C07D403/04
To view Chemocentryx’s complete patent history, request access »

Chemocentryx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chemocentryx Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Bio-Techne Corporation Minority
CSL Vifor Corporation Minority
GSK Corporation Minority
Gimv PE/Buyout Minority
You’re viewing 5 of 16 investors. Get the full list »

Chemocentryx ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

32.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,669

Rank

Percentile

Pharmaceuticals

Industry

of 895

Rank

Percentile

Biotechnology

Subindustry

of 396

Rank

Percentile

To view Chemocentryx’s complete esg history, request access »

Chemocentryx FAQs

  • When was Chemocentryx founded?

    Chemocentryx was founded in 1997.

  • Where is Chemocentryx headquartered?

    Chemocentryx is headquartered in Mountain View, CA.

  • What is the size of Chemocentryx?

    Chemocentryx has 178 total employees.

  • What industry is Chemocentryx in?

    Chemocentryx’s primary industry is Drug Discovery.

  • Is Chemocentryx a private or public company?

    Chemocentryx is a Private company.

  • What is the current valuation of Chemocentryx?

    The current valuation of Chemocentryx is .

  • What is Chemocentryx’s current revenue?

    The current revenue for Chemocentryx is .

  • How much funding has Chemocentryx raised over time?

    Chemocentryx has raised $316M.

  • Who are Chemocentryx’s investors?

    Alta Partners, Bio-Techne, CSL Vifor, GSK, and Gimv are 5 of 16 investors who have invested in Chemocentryx.

  • Who are Chemocentryx’s competitors?

    BioNTech, Sangamo Therapeutics, Immunocore Holdings, Arno Therapeutics, and Bristol-Myers Squibb are some of the 21 competitors of Chemocentryx.

  • When was Chemocentryx acquired?

    Chemocentryx was acquired on 20-Oct-2022.

  • Who acquired Chemocentryx?

    Chemocentryx was acquired by Amgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process